Jadenu (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Jadenu drug offered from Novartis Pharmaceuticals Corporation. This Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | deferasirox |
| SUBSTANCE NAME: | DEFERASIROX |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | GRANULE |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-05-18 |
| END MARKETING DATE: | 0000-00-00 |
Jadenu HUMAN PRESCRIPTION DRUG Details:
| Item Description | Jadenu from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 180(mg/1) |
| START MARKETING DATE: | 2017-05-18 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0713_ff2ffca0-5fb7-422c-b2bf-c8214c887007 |
| PRODUCT NDC: | 0078-0713 |
| APPLICATION NUMBER: | NDA207968 |
Other DEFERASIROX Pharmaceutical Manufacturers / Labelers:
